BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26416293)

  • 21. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
    Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
    BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer.
    Igawa S; Sasaki J; Otani S; Shirasawa M; Niwa H; Kusuhara S; Harada S; Kubota M; Katagiri M; Masuda N
    Oncology; 2016; 91(1):41-7. PubMed ID: 27234033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemetrexed-induced lower limb pseudocellulitis.
    Liau MM; Santosa A; Huang J; Tan LC
    Clin Exp Dermatol; 2017 Dec; 42(8):914-916. PubMed ID: 28815694
    [No Abstract]   [Full Text] [Related]  

  • 24. Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer.
    Ye L; Yang ZH; Fang SR; Gu W
    Chin Med J (Engl); 2017 Jul; 130(14):1757-1758. PubMed ID: 28685736
    [No Abstract]   [Full Text] [Related]  

  • 25. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflamed Actinic Keratoses After Pemetrexed.
    Cameron MC; Suárez AL; Kris MG; Myskowski PL
    Skinmed; 2016; 14(6):473-474. PubMed ID: 28031141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
    Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
    J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
    Barlési F; Tummino C; Tasei AM; Astoul P
    Lung Cancer; 2006 Dec; 54(3):423-5. PubMed ID: 17049669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
    Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
    Yoshida T; Okamoto T; Yano T; Takada K; Kohno M; Suda K; Takenoyama M; Oda Y; Maehara Y
    Anticancer Res; 2016 Dec; 36(12):6319-6326. PubMed ID: 27919952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
    Ciuleanu T; Brodowicz T; Zielinski C; Kim JH; Krzakowski M; Laack E; Wu YL; Bover I; Begbie S; Tzekova V; Cucevic B; Pereira JR; Yang SH; Madhavan J; Sugarman KP; Peterson P; John WJ; Krejcy K; Belani CP
    Lancet; 2009 Oct; 374(9699):1432-40. PubMed ID: 19767093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models.
    Pensec C; Gillaizeau F; Guenot D; Bessard A; Carton T; Leuillet S; Campone M; Neunlist M; Blottière HM; Le Vacon F
    Sci Rep; 2020 Jun; 10(1):9094. PubMed ID: 32499509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
    Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N
    Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
    Blackhall F; Kim DW; Besse B; Nokihara H; Han JY; Wilner KD; Reisman A; Iyer S; Hirsh V; Shaw AT
    J Thorac Oncol; 2014 Nov; 9(11):1625-33. PubMed ID: 25436797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lung cancer.
    Crinò L; Foglietta J; Hamzaj A
    J Thorac Oncol; 2007 May; 2(5 Suppl):S24-6. PubMed ID: 17457226
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemotherapy-induced inflammation of seborrheic keratoses due to pemetrexed treatment.
    Matsudate Y; Murao K; Kubo Y
    J Dermatol; 2017 May; 44(5):602-603. PubMed ID: 27345694
    [No Abstract]   [Full Text] [Related]  

  • 39. Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer.
    Xu B; Liu P; Yin Y; Liu P; Shu Y
    Biomed Pharmacother; 2013 Oct; 67(8):763-9. PubMed ID: 23790249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.